Logo

Pillar Biosciences

Pillar Biosciences Receives CMS Coverage for Pan-Cancer CDx Assay

The firm's next-generation sequencing-based test detects single nucleotide variants, insertions, and deletions in 22 genes.

In Brief This Week:, Hologic, Revvity, Pillar Biosciences, Mainz Biomed, More

News items for the week of Oct. 21, 2024.

Pillar Biosciences, AstraZeneca Partner on Liquid Biopsy Testing in Europe

AstraZeneca has partnered with several other firms on liquid biopsies, including Angle, Sophia Genetics, IMBdx, and Guardant Health.

FDA Approves Pillar Biosciences Pan-Cancer NGS Test for Solid Tumor Profiling

Previously approved for guiding EGFR- and KRAS-targeted therapy in specific tumor types, OncoReveal CDx can now be sold for general solid tumor profiling.

Beckman Coulter Life Sciences, Pillar Biosciences to Develop NGS Cancer Tests

Pillar will develop a series of tests for use on Beckman Coulter's Biomek NGeniuS Next Generation Library Preparation System.